- Status -
- Type New application
- Pre-PASC consultation Closed
- Pre-MSAC consultation Not yet started
- Outcome Pending
Application details
Reason for application
New MBS item (MSAC-PBAC co-dependent submission).
Service or technology in this application
Folate receptor alpha (FRɑ) is a protein that is expressed in nearly all ovarian cancers and can be overexpressed in ovarian cancer solid tumours while being minimally expressed in normal tissue. The FRɑ-positive expression status may be determined using a validated immunohistochemistry (IHC) assay to detect the percentage of viable tumour cells with membrane staining for FRɑ. The test is used to determine eligibility for a potential new PBS subsidised treatment, mirvetuximab soravtansine.
Type: Investigative technology
Medical condition this application addresses
The proposed treatment is intended for adults with epithelial ovarian, fallopian tube, or primary peritoneal cancer whose tumours are FRɑ-positive and are resistant to treatment with a platinum- containing chemotherapy regimen. Epithelial ovarian cancer is the most common type of ovarian cancer accounting for 90% of ovarian cancer cases.
Application documents
Application summary
PICO set
We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.
Consultation survey and deadlines
- PASC consultation: Closed Friday 8 November 2024
Any consultation received after this date will automatically be included in the MSAC consultation for this application. - MSAC consultation: TBA – please subscribe to the MSAC bulletin to be notified when this application is scheduled for MSAC consideration. The bulletin will also advise the closing date for consultation input.
Meetings to consider this application
- PASC meeting: 12–13 December 2024
- ESC meeting: -
- MSAC meeting: -
Outcome details
The outcome of this application is pending.